Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada.
Department of Psychiatry, McGill University, Montreal, QC, Canada.
Trials. 2019 Dec 12;20(1):717. doi: 10.1186/s13063-019-3747-z.
Some people with rare diseases rely on peer-led support groups for disease-specific education and emotional and practical support. Systemic sclerosis (SSc), or scleroderma, is a rare autoimmune connective tissue disease. Many people with SSc cannot access support groups, and, when support groups exist, they may not be sustained due to challenges that could be addressed via leader training. The Scleroderma Patient-centered Intervention Network (SPIN), along with SSc patient organization partners, developed a training program for SSc patient support group leaders, the Scleroderma Support group Leader EDucation (SPIN-SSLED) Program. We recently completed a feasibility trial in which we successfully delivered the program to two groups of support group leaders who reported a high level of satisfaction with the program and its delivery. The primary objective of the full-scale SPIN-SSLED trial is to evaluate the effect of the program on support group leaders' self-efficacy for carrying out their leadership role. Secondary objectives include evaluating effects on leader burnout, leader satisfaction (participation efficacy), and emotional distress.
METHODS/DESIGN: The SPIN-SSLED trial is a pragmatic randomized controlled trial (RCT) in which 180 support group leaders will be randomly allocated to training groups of 6 participants each or to a waitlist control. We will use a partially nested RCT design to reflect dependence between individuals in training groups, but not in the waitlist control. Participants allocated to the training program will receive the 13-module SPIN-SSLED Program, delivered via webinar over the course of 3 months in weekly 60-90-min sessions. The primary outcome is leader self-efficacy, measured by the Scleroderma Support Group Leader Self-efficacy Scale post-intervention. Secondary outcomes are leader self-efficacy at 3 months post-intervention, and leader burnout, volunteer job satisfaction (participation efficacy), and emotional distress post-intervention and at 3 months post-intervention.
The SPIN-SSLED trial will test whether a training program for SSc patient support group leaders increases the self-efficacy of group leaders to carry out leadership tasks. The program has the potential to significantly improve the effectiveness and sustainability of existing SSc support groups, to increase the number of available support groups, and to be adapted for other chronic diseases.
ClinicalTrials.gov, NCT03965780. Registered on 29 May 2019.
一些罕见病患者依赖于由患者主导的支持小组,以获取特定于疾病的教育以及情感和实际支持。系统性硬化症(SSc),又称硬皮病,是一种罕见的自身免疫性结缔组织疾病。许多 SSc 患者无法获得支持小组的帮助,而当支持小组存在时,由于领导力培训可以解决的挑战,它们可能无法持续存在。硬皮病患者为中心的干预网络(SPIN)与硬皮病患者组织合作伙伴一起,为 SSc 患者支持小组的领导者开发了一项培训计划,即硬皮病支持小组领导者教育(SPIN-SSLED)计划。我们最近完成了一项可行性试验,成功地向两组支持小组的领导者提供了该计划,他们对该计划及其实施方式表示高度满意。SPIN-SSLED 试验的主要目标是评估该计划对支持小组领导者履行其领导角色的自我效能的影响。次要目标包括评估对领导者倦怠、领导者满意度(参与效能)和情绪困扰的影响。
方法/设计:SPIN-SSLED 试验是一项实用的随机对照试验(RCT),其中将有 180 名支持小组的领导者被随机分配到每组 6 名参与者的培训组或候补对照组。我们将使用部分嵌套 RCT 设计来反映培训组中个体之间的依赖性,但候补对照组中没有依赖性。被分配到培训计划的参与者将接受为期 3 个月的 13 个模块的 SPIN-SSLED 计划,通过网络研讨会每周进行 60-90 分钟的课程。主要结局指标是领导者的自我效能感,通过干预后硬皮病支持小组领导者自我效能感量表来衡量。次要结局指标是干预后 3 个月时的领导者自我效能感,以及干预后和 3 个月时的领导者倦怠、志愿者工作满意度(参与效能)和情绪困扰。
SPIN-SSLED 试验将检验针对 SSc 患者支持小组领导者的培训计划是否可以提高小组领导者履行领导任务的自我效能感。该计划有可能显著提高现有 SSc 支持小组的有效性和可持续性,增加可获得的支持小组数量,并适用于其他慢性疾病。
ClinicalTrials.gov,NCT03965780。于 2019 年 5 月 29 日注册。